

IDENTIFYING AND TREATING ASYMPTOMATIC MVD

Vetmedin® is the only treatment that delays the onset of heart failure in dogs with asymptomatic MVD*. Don't watch and wait when MVD murmurs are detected; investigate for cardiomegaly to identify which dogs will benefit from Vetmedin®. This algorithm has been developed to help you follow a new "Listen, Investigate, Treat" approach to dogs with MVD murmurs.






LISTEN

MVD MURMUR \geq GRADE 3/6




INVESTIGATE

CHEST X-RAY




If VHS increased by \geq 0.5 over 6 months

CARDIAC ULTRASOUND



LA:Ao and LVIDDN



TREAT

Prescribe Vetmedin® at the preferable daily dose (0.25 mg/kg BID)

vetmedin®

TODAY. NOT ONE DAY.

There are two well-established ultrasound measurements that are used to assess the size of the left side of the heart; the LA:Ao ratio measures the size of the left atrium, the LVIDDN measures the size of the left ventricle.

The LA:Ao ratio compares the size of the left atrium to the size of the aortic root. The normal LA:Ao ratio is <1.6 when measured using the short axis view.

The LVIDDN measures the internal diameter of the left ventricle in diastole normalised according to body weight. The normal LVIDDN is <1.7.

vetmedin®

TODAY. NOT ONE DAY.

Vetmedin® Chew 1.25 mg, 5 mg and 10 mg chewable tablets for dogs

Active substance: Pimobendan. Uses: For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid valve regurgitation). (See also section 4.9 of the SPC). For the treatment of dilated cardiomyopathy in the preclinical stage (asymptomatic with an increase in left ventricular end-systolic and end-diastolic diameter) in Doberman Pinschers following echocardiographic diagnosis of cardiac disease (see sections 4.4 and 4.5 of the SPC). For the treatment of dogs with myxomatous mitral valve disease (MMVD) in the preclinical stage (asymptomatic with a systolic mitral murmur and evidence of increased heart size) to delay the onset of clinical symptoms of heart failure (see sections 4.4 and 4.5 of the SPC). Further information: Please refer to the product packaging and leaflets for information about side effects, precautions, warnings and contra-indications. Legal category: UK: POM-V, IE: POM.

Vetmedin® contains pimobendan. UK: POM-V IE: POM. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK Tel: 01344 746959 (sales) or 01344 746957 (technical), IE Tel: 01 291 3985 (all queries). Email: vetenquiries@boehringer-ingelheim.com. Vetmedin® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under licence. © 2022 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: Jan 2022. UI-CAN-0026-2022. Use Medicines Responsibly.